DOCSLIB.ORG

What to Consider Before Contacting a Venture Capital Investor

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
What to Consider Before Contacting a Venture Capital Investor Deliverable 6: Network of private investors Background material for AAL project participants March 2014 (updated NHG 22.12.2016) Copyright statement AAL2Business - Report titled “Network of private investors - Background material for AAL project participants“ Report for Ambient Assisted Living Association, Brussels Date April 2014 Author(s) Nordic Healthcare Group Responsible Administrator: AAL Association Brussels Project name: AAL2Business Publisher: Ambient Assisted Living Association Rue de Luxembourg, 3, 2nd floor B-1000 Brussels, Belgium Phone +32 (0)2 219 92 25 email: [email protected] About Ambient Assisted Living Association: The Ambient Assisted Living Association (AALA) is organizing the Ambient Assisted Living Joint Programme (AAL JP). The AAL JP aims at enhancing the quality of life of older people and strengthening the industrial base in Europe through the use of Information and Communication Technologies (ICT). Therefore, the AAL JP is an activity that operates in the field of services and actions to enable the active ageing among the population. The programme is financed by the European Commission and the 22 countries that constitute the Partner States of this Joint Programme. See more at: http://www.aal-europe.eu/ The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the AALA. The AALA does not guarantee the accuracy of the data included in this study. Neither the AALA nor any person acting on the AALA’s behalf may beheld responsible for the use which may be made of the information contained therein. All rights reserved by AALA. © 2014 Ambient Assisted Living Association, Brussels 2 Contents 1 Introduction and content overview 2 Funding opportunities and availability in Europe 3 Considerations before seeking funding 4 Choosing the right type of funding 5 Investor contacts and event listings • Accelerator Programs & Business angels • Venture capital • Events • Other useful sources 3 Introduction to material . This material has been prepared to aid potential projects in choosing and seeking out the most suitable funding options . First, different sources of equity funding are introduced. Second, different criteria are presented to help choose the best suiting source of funding for each project . Lastly, central Venture Capital companies, local Business Angel networks and organizations, relevant events in Europe and other resources are shortlisted − The shortlist is not exhaustive and serves instead as a potential first place and guideline to start searching for suitable investors − More information and more investors can be found through online searches to complement the provided material − Individual business angels can be targeted efficiently through national or local business angel networks . The material targets startups and early-stage companies . The material concentrates on different forms of equity financing. Debt financing is left out of the scope . All of the companies and organizations presented in the material are based in Europe 4 Overview of material 1. Introduction and overview 3. Considerations before 4. Choosing the right type of 5. Investor contacts and event seeking funding funding listings Introduction to material European Business Angel Networks 5 key Angel Networks shortlisted, in alphabetical order Overview of material The appropriate source of funding depends on the maturity of the Network Region Description Website Phone Email company and the amount of funding required AngelList is a platform connecting startups and AngelList Europe https://angel.co/ [email protected] 1. Introduction and overview 2. Funding opportunities and 3. Choosing the right type of 4. Investor contacts and event investors with country-specific sites availability in Europe funding listings > 10 000 000€1,2 Overview of material The European Trade Association for Business Angels, http://www.eban.or (+32) 2 626 20 Eban Europe [email protected] 1. Introduction and overview Seed Funds and other Early Stage Market Players g/ 62 1 Venture Capital Companies, A network of 400+ business angels looking to invest http://www.envesto +44 (0)20 7240 [email protected]. Private Equity Companies Envestors UK 7 between £20k to £2m in early stage companies rs.co.uk/ 0202 uk 0,8 Gust is a global platform for the sourcing and Gust International http://gust.com/ [email protected] Short introduction to management of early-stage investments Descriptions of funder types presentation and overview of Discussion of available 0,6 Venture Capital Companies, contents. funding and short statistical and suggestions on when each type is appropriate Business Angels The StartAngels Network is a platform for business overview. angel investors StartAngels http://en.startangel Switzerland Our mission is to offer our members access to [email protected] Network s.ch/ 0,4 attractive investment opportunities in early-stage Accelerator Programs, Swiss companies. 5 Amountof funding required Crowdfunding, It should be kept in mind that Business Angels operate more locally than Venture Capital companies, and thus each Listing of key investor 0,2 Early-stage team/entrepreneur interested in Angel Investors should look up their local Angels from AngelList/Eban or the respective networks, funding events and Business Angels other useful resources portals in their home country < 10 000€ 0 29 0Startup 0,5 1 Maturity1,5 of the company2 2,5Established company3 with revenue3,5 7 19 Short introduction to presentation and overview of European Venture Capital companies in the health tech market contents. 20 major VC companies shortlisted, in alphabetical order (1/4) Company Country Description Website Phone Email Advent Venture Partners is one of Europe's most http://www.adventv +44 (0)20 7932 Descriptions of funder types Descriptions of funder types Advent Ventures UK successful growth and venture capital investors in [email protected] entures.com/ 2100 market-leading tech and life sciences businesses. Aescap invests in companies using technologies that The are sufficiently mature to yield realistic product- http://www.aescap. + 31 20 570 29 [email protected] / Aescap Venture and suggestions on when and suggestions on when Netherlands opportunities in combination with the ability to com/ 40 [email protected] 2. Funding opportunities and generate non dilutive financing from licensing deals. Early-stage investor with a focus on enabling technologies and tools which are transforming http://www.ariadne +44 (0)20 3356 Ariadne Capital UK each type is appropriate each type is appropriate established businesses and creating the digital capital.com/ 9690 availability in Europe ecosystem of health and lifestyle BB BIOTECH VENTURES is a healthcare-dedicated venture capital firm. We manage funds (limited http://www.bbbiote +41 44 267 67 BB Biotech Ventures Switzerland partnerships) that invest in private companies [email protected] chventures.com/en/ 00 developing and marketing drugs and medical devices or providing healthcare services. Earlybird invests €200k to €15m in technology Earlybird Venture http://www.earlybir Germany companies that have the potential to impact large +493046724700 [email protected] Capital d.com/ markets. 35 The Life sciences sector is the most common target for Venture Capital investments in EU countries Venture Capital Investments in Europe by Sector Life sciences 28,4 Computer & consumer electronics 19,0 Communications 18,2 Energy & environment 11,0 Consumer goods & retail 5,7 Consumer services 4,8 Listing of key investor Financial services 4,1 Business & industrial products 3,5 Business & industrial services 1,7 Chemicals & materials 1,5 networks, funding events and Transportation 1,1 Construction 0,3 Agriculture 0,3 Real estate 0,2 other useful resources Unclassified 0,1 0,0 5,0 10,0 15,0 20,0 25,0 30,0 % of total VC investments 11 Discussion of available funding and short statistical overview. 5 Contents 1 Introduction and content overview 2 Funding opportunities and availability in Europe 3 Considerations before seeking funding 4 Choosing the right type of funding 5 Investor contacts and event listings • Accelerator Programs & Business angels • Venture capital • Events • Other useful sources 6 The Life sciences sector is the most common target for Venture Capital investments in Europe 2015 Venture Capital Investments in Europe by Sector Life sciences 33,9 % Computer & consumer electronics 19,9 % Communications 18,6 % Consumer goods & retail 7,0 % Consumer services 5,8 % Energy & environment 3,6 % Business & industrial products 3,3 % Financial services 2,8 % Business & industrial services 1,9 % Chemicals & materials 1,2 % Transportation 1,1 % Agriculture 0,2 % Real estate 0,2 % Construction 0,0 % Unclassified 0,4 % 0% 5% 10% 15% 20% 25% 30% 35% 40% % of total VC investments Source: Invest Europe 7 European venture capital investments in recent years In 2015, the total VC investments made in Europe summed There are notable differences between VC investments per up to 3,81€bn GDP in European countries Total investment, €bn VC investment as share of GDP (%) 7 0,12% Denmark 6 0,10% 5 0,08% Luxembourg 4 0,06% 6,31 3 6,01 United Finland Kingdom 0,04% Ireland France 2 Portugal Sweden 3,82 3,66 3,70 3,64 3,81 3,41 Netherlands 3,21 Norway 0,02% Hungary 1 Bulgaria Belgium Germany Czech Republic Spain Poland Romania Austria 0 0,00% Italy 2007 2008 2009 2010 2011 2012 2013 2014 2015 1 10 100 1000 Total VC investment (€M, log scale) Source: Invest Europe 8 Contents 1 Introduction
Load more

Recommended publications
  • 80 Investors: Longevity in Switzerland 3Wventures
    80 Investors: Longevity in Switzerland 3wVentures 3wVentures provides seed money and venture capital to international internet startups. As 3wVentures' clients focus on early stage projects and prototypes, the company's investments and co-investments target a volume of up to USD 250,000. 3wVentures is located in Switzerland and backed by Yves Latour and Arvin Zuberbuehler. 3wVentures has invested early stage venture capital in these startup companies: forAtable.com, Lunchgate, UEPAA! etc. Web site: 3wventures.com Number of Investments: 44 Total Investments: $23.3M Founded in: 2007 Based in: Herisau, Switzerland Sector: P3, AgeTech Investment in Switzerland companies: Pregnolia, Abionic Stages: Early Stage Venture, Seed 231 Aescap Venture Aescap 2.0 is an open-end fund that invests in publicly listed biotech / life sciences companies. It invests in highly innovative companies that develop and market new medicines and to a lesser extent diagnostics and/or medical devices. Entry into and exit from the fund is possible twice per month. The life sciences market is a large and fast-growing market where breakthrough innovations can be harnessed in a global and profitable manner. Aescap 2.0 has a focused portfolio, investing in approximately 18 companies. Within this focus it will ensure that the portfolio is diversified over different diseases and company development phases. The Fund’s objective is to make an annual net return (after deduction of costs) of 20% over the mid-term (4-5 years). Web site: aescap.com Number of Investments: 26 Total Investments: $30.5M Founded in: 2005 Based in: Amsterdam, The Netherlands Sector: Regenerative Medicine Investment in Switzerland companies: Vivendy Therapeutics Stages: Early Stage Venture, Late Stage Venture 2 Angel Investment Network Angel Investment Network is a London-based investment company founded in 2004 whose aim is to connect entrepreneurs and investors.
    [Show full text]
  • Gimv Invests in Biopharmaceutical Company Complix
    Antwerp, 26 June 2013, 7:30 AM CET Gimv invests in biopharmaceutical company Complix Gimv and Gimv managed Biotech Fonds Vlaanderen invest in Complix, a biopharmaceutical company focused on the discovery and development of novel therapeutics based on its AlphabodiesTM platform. This investment is part of a total Series B equity financing round of EUR 12 million from a syndicate of important life sciences investors, co-led by new investors Gimv and Edmond de Rothschild Investment Partners. Complix is a biopharmaceutical company developing a pipeline of therapeutics, called AlphabodiesTM, mainly focused on oncology and autoimmunity. Alphabodies are a revolutionary class of protein therapeutics that combine the attractive features of antibodies, including high target specificity and affinity, with the benefits from small chemical drugs such as extreme stability and their capacity to penetrate cells. As a result of these unique features, Alphabodies can tackle a broad range of diseases where treatment options today are limited or non-existent. Complix is headquartered in Hasselt (Belgium) at the Life Sciences incubator BioVille, and has research facilities in Ghent (Belgium) and in Luxembourg. Since its founding in 2008 Complix has raised a total of EUR 26 million in funding, including the EUR 12 million capital round announced today. This financing round will be used to develop a first set of therapeutic Alphabodies for treatment of cancer and auto- immune indications, and to further develop and validate the company’s unique Alphabody platform. Mr Patrick Van Beneden, Partner at Gimv, comments: “We are very excited by the Complix opportunity because it perfectly fits in our Health & Care platform strategy for biotech investments.
    [Show full text]
  • Annual Report 2018 - 2019
    ANNUAL REPORT 2018 - 2019 ANNUAL REPORT 2018 - 2019 LEADING OUR PORTFOLIO COMPANIES FOR THE BENEFIT OF OUR ECONOMY. CONTENTS 1. Message from Chairman and CEO 5 2. Business model and investment strategy 9 3. Value creation starting from 4 central themes 23 4. Results and activity report 35 5. Key figures 41 6. Share and shareholders 45 7. Corporate Governance Statement 49 8. Annual Accounts 77 9. Contact 141 INVESTMENT PORTFOLIO EUR 1.1 BILLION OUR 55 PORTFOLIO COMPANIES JOINTLY REALISE A TURNOVER OF MORE THAN EUR 2.75 BILLION AND EMPLOY 14 000 PROFESSIONALS FOCUS ON VALUE CREATION FROM 4 PLATFORMS CONNECTED HEALTH SMART SUSTAINABLE CONSUMER & CARE INDUSTRIES CITIES 4 OFFICES WITH MULTIDISCIPLINARY TEAMS: ANTWERP, PARIS, THE HAGUE, MUNICH 39 YEARS’ EXPERIENCE IN PRIVATE EQUITY OVER THE LAST 5 YEARS INVESTED IN 932 EUR MILLION 46 COMPANIES PROCEEDS FROM 1 520 EUR MILLION 48 EXITS MESSAGE FROM CHAIRMAN AND CEO1 6 ANNUAL REPORT 2018-2019 The world around us is changing at an incredible pace. Last year we were still talk- ing about an improving economy that had moved up several gears; today, barely a year later, we see this economic upswing under threat from various geopolitical and macroeconomic factors. Trade relations are more difficult, the power posi- IMPACT: MEETING CRUCIAL tions and therefore also the relationships between CHALLENGES TOGETHER the major world economic powers are shifting, as evidenced by the never-ending story of Brexit. Gimv goes looking for the market leaders of Last year, climate and the environment concerns tomorrow, together with which it can make a vi- topped the political and economic agenda, calling tal difference, year after year.
    [Show full text]
  • The Acceleration Point: Why Now Is the Time for European Venture Capital Invest Europe the Acceleration Point: Why Now Is the Time for European Venture Capital
    EUROPEAN VENTURE CAPITAL The Acceleration Point: Why Now is the Time for European Venture Capital Invest Europe The Acceleration Point: Why Now is the Time for European Venture Capital C Invest Europe The Acceleration Point: Why Now is the Time for European Venture Capital Contents What’s in this report 01 Foreword Section One: Section Two: Why Now is the Time Why Europe? Europe’s Innovation for European Venture Capital Why Now? Pages 04-15 Economy Pages 16-22 By Nenad Marovac Invest Europe Vice-Chair 1 2 Page 02 Page 04 Page 17 A strong economy committed European tech cities to growth Page 18 Page 05 Benelux European VC is experienced Page 19 Page 07 France, Spain & Switzerland Proven ability to create global leaders To find out more about Invest Europe please visit: Page 20 Page 09 Germany Increased exit options www.investeurope.eu Page 21 Page 11 UK & Ireland Outsized returns in a low-yield environment Page 22 Scandinavia Page 13 Robust fundraising Page 15 Page 23 Europe’s hottest sectors In conclusion For PDF download to your computer: Page 24 Please visit our website at www.investeurope.eu if you would like to download this report as References and data methodology a standalone PDF. Invest Europe The Acceleration Point: Why Now is the Time for European Venture Capital Foreword Foreword by Nenad Marovac 02 Why now is the time for European venture capital The European venture capital (VC) industry has reached an acceleration point. Europe’s prospering economies, the unprecedented rise of the European tech industry and the region’s experienced fund managers make it the right time to invest in European venture capital.
    [Show full text]
  • Private Equity & Venture Capital
    VOLUME 14, ISSUE 6 ■ AUGUST 2018 PRIVATE EQUITY & VENTURE CAPITAL SPOTLIGHT THE RISE OF VENTURE AND IN THIS ISSUE GROWTH CAPITAL IN EUROPE €11bn in capital has already been secured by venture and growth capital funds focused on Europe that have closed this FEATURE 3 year; this is the highest figure seen at this stage in recent The Rise of Venture years. We put activity in the region under the microscope, examining the economic factors that have contributed to and Growth Capital in this. Europe Find out more on page 3 INDUSTRY NEWS 7 THE FACTS ■ Private Equity in the 9 PRIVATE EQUITY IN THE NORDIC Nordic Region REGION ■ Public Pension Funds 12 Investing in Private With the capital raised by managers based in the Nordic Equity region reaching record highs, we take a look at the growing private equity market in terms of fundraising activity, investor make-up and largest exits in the region. CONFERENCES 14 Find out more on page 9 RECENTLY RELEASED: THE 2018 PREQIN PRIVATE CAPITAL FUND TERMS THE 2018 PRIVATE CAPITAL All data in this newsletter ADVISOR can be downloaded to PREQIN FUND TERMS ADVISOR Excel for free Order Your Copy Download Sample Pages Sign up to Spotlight, our free monthly newsletter, providing insights into performance, investors, deals and fundraising, powered by Preqin data: Alt Credit Intelligence European and US Fund Services Awards: Best Data and Information Provider | Africa Global Funds Awards 2016: Best Research and Data Provider | The Queen’s SIGN UP Award for Enterprise: International Trade | HedgeWeek Global Awards:
    [Show full text]
  • 4Oct200722045121 1Dec200517045043
    4OCT200722045121 This prospectus (the ‘‘Prospectus’’) relates to the initial offering (the ‘‘Offering’’) to subscribe for up to A75 million of new common shares in Ablynx NV (the ‘‘Company’’ or ‘‘Ablynx’’), with VVPR strips (the ‘‘VVPR Strips’’). This amount of New Shares with VVPR Strips may be increased by up to 15 per cent, to an amount of A86.25 million (the ‘‘Increase Option’’, the new shares initially offered and the shares offered as a result of the possible exercise of the Increase Option jointly being referred to as the ‘‘New Shares’’). Any decision to exercise the Increase Option will be announced, at the latest, on the date the Offer Price is announced. JPMorgan and KBC Securities (the ‘‘Joint Global Coordinators’’) will be granted an over-allotment option by the Company (the ‘‘Over-allotment Option’’), exercisable as of the listing date (the ‘‘Listing Date’’) and until 30 days thereafter, corresponding to up to 15 per cent of the New Shares subscribed for in the Offering for the sole purpose of allowing the Joint Global Coordinators to cover over-allotments, if any. The existing shares covered by the Over-allotment Option (the ‘‘Additional Shares’’ and, together with the New Shares, the ‘‘Offered Shares’’) and the New Shares issued upon exercise of the Over-allotment Option, if any, will not have a separate VVPR Strip. The Offered Shares are offered to the public in Belgium (including to employees, consultants and independent directors of the Company in Belgium) and, pursuant to a private placement, to institutional investors, both within and outside Belgium and to employees, consultants and independent directors of the Company outside Belgium.
    [Show full text]
  • Building Momentum in Venture Capital Across Europe – France, Germany, Italy, Spain and the United Kingdom
    France, Germany, Italy, Spain and the United Kingdom ∆Building Momentum in Venture Capital across Europe Imprint Published by Bpifrance 27–31, avenue du Général Leclerc 94710 Maisons-Alfort Cedex, France www.bpifrance.fr Cassa depositi e prestiti SpA (CDP) Via Goito 4 00185 Rome, Italy www.cdp.it Instituto de Crédito Oficial (ICO) Paseo del Prado 4 28014 Madrid, Spain www.ico.es British Business Bank Foundry House 3 Millsands Sheffield S3 8NH, United Kingdom www.british-business-bank.co.uk KfW Bankengruppe (KfW) Palmengartenstraße 5-9 60325 Frankfurt am Main, Germany www.kfw.de Authors Miguel Fernández Acevedo (ICO) Matt Adey, British Business Bank Claudio Bruno (CDP) Gino del Bufalo (CDP) Alexandre Gazaniol, Bpifrance Dr Vivien Lo (KfW) Dr Georg Metzger (KfW) Blanca Navarro Perez (ICO) Dan van der Schans, British Business Bank Baptiste Thornary, Bpifrance Editor Dr Georg Metzger (KfW) Layout and Design Bettina Apfelbach (KfW) Iris Brandt (KfW) Picture Credits Getty Images / Photograf Westend61 December 2016 Table of Contents Greetings 5 Foreword 7 1. General Part 11 1.1 Venture capital: what it is and why it is important 13 1.2 The EU venture capital market 14 1.3 Fostering the European VC market 23 1.4 Recommendations for building momentum in the venture capital markets in Europe 26 2. Country Reports 29 2.1 France 31 2.1.1 Development of the VC market 31 2.1.2 Role of public institutions 32 2.1.3 Specific challenges and needs 33 2.1.4 Policy recommendations 34 2.2 Germany 35 2.2.1 Development of the VC market 35 2.2.2 Role of the national
    [Show full text]
  • Study on Equity Investments in Europe: Mind the Gap
    Study on Equity Investments in Europe: Mind the Gap STUDY ON EQUITY INVESTMENTS IN EUROPE: MIND THE GAP European Commission Directorate-General for Research and Innovation Unit RTD TF.3 – Financial Instruments Contact Stéphane Ouaki Email sté[email protected] [email protected] European Commission B-1049 Brussels Manuscript completed in February 2021. 1st edition. This document has been prepared for the European Commission, however it reflects the views only of the authors, and the European Commission is not liable for any consequence stemming from the reuse of this publication. More information on the European Union is available on the internet (http://europa.eu). PDF ISBN 978-92-76-28648-6 doi: 10.2777/001375 KI-04-21-014-EN-N Luxembourg: Publications Office of the European Union, 2021 © European Union, 2021 The reuse policy of European Commission documents is implemented based on Commission Decision 2011/833/EU of 12 December 2011 on the reuse of Commission documents (OJ L 330, 14.12.2011, p. 39). Except otherwise noted, the reuse of this document is authorised under a Creative Commons Attribution 4.0 International (CC-BY 4.0) licence (https://creativecommons.org/licenses/by/4.0/). This means that reuse is allowed provided appropriate credit is given and any changes are indicated. For any use or reproduction of elements that are not owned by the European Union, permission may need to be sought directly from the respective rightholders. Image credits: Cover page: © Lonely #46246900, ag visuell #16440826, Sean Gladwell #6018533, LwRedStorm #3348265, 2011; kras99 #43746830, 2012. Source: Fotolia.com.
    [Show full text]
  • SL Capital Barometer 2016.Q2
    Q2 2016 Preliminary Data Private Equity BAROMETER Figures based on preliminary quarterly data from Q2 2016 Europe’s specialist private equity information provider. 1 Q2 2016 Preliminary Data Key Findings Overall European private equity ➤ The number of European private-equity-backed deals declined by 8% in the second quarter of 2016, from 381 transactions in Q1 to 350. ➤ Combined deal value improved in the second quarter, rising by 66%. ➤ The average deal value in the second quarter (€86.1m) was 81% higher than that of the first quarter (€47.6m). ➤ Overall, the year to Q2 2016 witnessed a shift towards larger deals; total deal value increased by 2%, while total volume slipped by 17%. As a result, average deal value increased by 23%. Buyouts ➤ The aggregate value of buyouts in the year to Q2 2016 (€107.4bn), was down a nominal 0.2% on the previous 12 months, while the number of deals (560) represented a 4% decline. ➤ Deal numbers increased to 148 in the second quarter, a rise of 15 from the 133 deals completed in the first quarter, and registered the highest total seen over the last six quarters. ➤ Aggregated value increased markedly, rising by 80% from the previous quarter’s total of €15.2bn, to €27.3bn. ➤ An abundance of dealflow in the small-cap (sub-€100m) and large-cap (€1bn+) ranges was responsible for the increase in the total number of buyouts in the second quarter. ➤ The small-cap range improved relative to the first quarter, increasing from 88 to 97 transactions; value rose by 25% from €3.3bn to €4.2bn.
    [Show full text]
  • INTERIM REPORT for the Period from 1 January 2007 to 30 September 2007 INTERIMSTATEMENT REPORT of the INVESTMENT MANAGER
    INTERIM REPORT for the period from 1 January 2007 to 30 September 2007 INTERIMSTATEMENT REPORT OF THE INVESTMENT MANAGER INVESTMENT MANAGER’S REPORT PRINCESS’ NET ASSET VALUE UP 11% IN 2007 Princess continued its positive development during the third quarter of 2007. Despite the recent turbulence in the finan- cial markets and the weakness of the US dollar, the net asset value (NAV) increased by another 3.1% during the past three months to stand at EUR 98.64 per share at the end of Sep- Princess Private Equity Holding Limited (“Princess”) is an investment holding company tember 2007. A number of the underlying partnerships in the portfolio – especially buyout funds and partnerships in the domiciled in Guernsey that invests in private equity and private debt investments. North American region – reported write-ups, leading to reval- uations in the Princess private equity portfolio. Adjusted for Investments include primary and secondary fund investments, direct investments and the dividend that was paid out in April, the NAV has gained 11% since the beginning of the year. listed private equity. Princess aims to provide shareholders with long-term capital The recent concerns over the US subprime mortgage market growth and an attractive dividend yield. that spilled over to the wider credit market had no significant impact on the NAV development of the Princess portfolio and are not expected to materially affect the portfolio. Princess has no direct sub-prime exposure and while it has some The shares deliverable in the form of co-ownership interests in a global bearer certifi- exposure to the credit market through mezzanine invest- ments under its special situations allocation, these invest- cate are traded on the Frankfurt Stock Exchange.
    [Show full text]
  • Annual Report 2011-2012
    Annual Report 2011-2012 Table of contents A word from our Chairman and CEO 1 Gimv at a glance 4 Highlights 2011-2012 6 Results and key figures 12 Buyouts & Growth 16 Overview Buyouts & Growth-portfolio incl. Gimv-XL 20 Venture Capital 27 Overview Venture Capital-portfolio 31 Funds & Joint Ventures 38 Share and shareholders 40 Human capital 43 Occurrences after closing of the financial year and prospects 45 Corporate governance statement 46 Board of Directors 46 Members 46 Composition 50 Operation 51 Evaluation 52 Remuneration 52 Guidelines and code of conduct 52 Advisory committees within the board of directors 52 Audit Committee 52 Remuneration Committee 54 Nomination Committee 54 Management Committee 55 Members 55 Evaluation 56 Remuneration 56 Share ownership 56 Partners' council 57 Capital 59 Internal control and risk management 60 Remuneration report 63 External audit 68 Annual accounts 69 Limited consolidation 71 1 Consolidated income statement 71 2 Consolidated balance sheet 72 3 Changes in equity 74 4 Simplified cash flow statement 77 5 Main valuation rules 77 6 Explanation income statement 77 7 Explanation balance sheet 81 The consolidated financial statements are expressed in thousands of euros unless otherwise mentioned. Gimv NV Good company for companies T +32 3 290 21 00 | F +32 3 290 21 05 | @ [email protected] www.gimv.com Karel Oomsstraat 37, 2018 Antwerpen, Belgium Annual Report 2011-2012 8 Auditor's statement 84 Statutory consolidation 85 1 Consolidated income statement 85 2 Consolidated balance sheet 86 3 Changes in equity
    [Show full text]
  • Gimv Invests EUR 3.0 Million in Polish Contact Center Operator Datacontact
    Antwerp - Warsaw / 6 October 2010 / 7:30 CET Gimv invests EUR 3.0 million in Polish contact center operator DataContact Gimv invests EUR 3.0 million (PLN 12.0 million) growth capital in DataContact, a fast-growing Polish provider of outsourced contact center services. Eric Ignoul, former CEO of leading Belgian call center IP Globalnet, will become independent industry expert on the company’s Supervisory Board. DataContact ( www.datacontact.pl ) was founded in 1995 as the first contact center operator in Poland. Between 2001 and 2010 the company was subsidiary of Axel Springer AG under the name of Axel Springer Kontakt. The group is headquartered in Warsaw and currently operates 185 workstations in two locations. It focuses on customer service, marketing and sales activities for the Polish and German markets. The group offers both inbound and outbound call services as well as non-voice services. Amongst its customers, DataContact has several long-term tier-1 clients from multiple industries, including publishing, IT, financial services and transportation. The company is led by industry veteran Jacek Barankiewicz, who holds the remaining shares in the company next to Gimv. Gimv will have two representatives (Jan Dewijngaert and Radoslav Tausinger) on the company’s Supervisory Board, next to Eric Ignoul, who will hold the position of independent industry expert. The proceeds of this financing will be used to support its further growth in the Polish market, including opening of new contact centers. The first one is to be opened in Stalowa Wola, South East Poland, in November 2010. The investment was initiated and will be managed through Gimv's Pragues presence, which is used as a hub for Gimv’s investments for the Central European market.
    [Show full text]